Quetiapine extended-release (Seroquel-XR) versus amitriptyline monotherapy for treating patients with fibromyalgia: A 16-week, randomized, flexible-dose, open-label trial

Psychopharmacology

Volumn 231, Issue 12, 2014, Pages 2525-2531

  Calandre, Elena P ^a   Rico Villademoros, Fernando ^a   Galán, Jaime ^b   Molina Barea, Rocio ^a   Vilchez, Juan S ^a   Rodriguez Lopez, Carmen M ^a   Hidalgo Tallon, Javier ^a   Morillas Arques, Piedad ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

Author keywords

Amitriptyline; Efficacy; Fibromyalgia; Quetiapine XR; Tolerability

Indexed keywords

AMITRIPTYLINE; QUETIAPINE; DELAYED RELEASE FORMULATION; DIBENZOTHIAZEPINE DERIVATIVE; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPESTHESIA; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NIGHTMARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP QUALITY; SOMNOLENCE; TACHYCARDIA; TINNITUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA; YOUNG ADULT; ADOLESCENT; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG THERAPY; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; SLEEP; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; DELAYED-ACTION PREPARATIONS; DEPRESSION; DIBENZOTHIAZEPINES; FIBROMYALGIA; HUMANS; MIDDLE AGED; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902163348     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3422-0     Document Type: Article

References (29)

1. Alonso J, Prieto L, Antó JM (1995) The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 104:771-776
2. Badia X, Muriel C, Gracia A et al (2003) Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica. Med Clin (Barc) 120:52-59
3. Bandelow B, Chouinard G, Bobes J et al (2010) Extended-quetiapine fumarate (quetiapine XR): a one-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305-320
4. Barkhuizen A (2002) Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 28:261-290
5. Boyle J, Eriksson ME, Gribble L et al (2012) Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 35:2451-2458
6. Calandre EP, Rico-Villademoros F (2012) The role of antipsychotics in the management of fibromyalgia. CNS Drugs 6:135-153
7. Calandre EP, Morillas-Arques P, Molina-Barea R et al (2011) Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskeletal Disord 12:95
8. Coe HV, Hong IS (2012) Safety of low doses of quetiapine when used for insomnia. Ann Pharmacother 46:718-22
9. Cohrs S, Rodenbeck A, Guan Z et al (2004) Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacol (Berl) 174:421-429
10. Esteve-Vives J, Rivera Redondo J, Salvat Salvat MI et al (2007) Propuesta de una versión de consenso del Fibromyalgia Impact Questionnaire (FIQ) para la población española. Reumatol Clin 3:21-24
11. Fisher DS, Handley SA, Flanagan RJ et al (2012) Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation and other factors. Ther Drug Monit 34:415-421
12. Gao K, Kemp DE, Fein E et al (2011) Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 72:1063-1071
13. Guy W (1976) ECDEU assessment manual for psychopharmacology - revised (DHEW Publ No ADM 76-338). U.S. Department of Health, Rockville
14. Häuser W, Petzke F, Sommer C (2010) Comparative efficacy and harms of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome. J Pain 11:505-521
15. Häuser W, Wolfe F, Tölle T et al (2012) The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 26:297-307
16. Hidalgo J, Rico-Villademoros F, Calandre EP (2007) An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry 31:71-77
17. Katzman MA, Brawman-Mintzer O, Reyes EB et al (2011) Extended-release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 26:11-24
18. Le Marshall KF, Littlejohn GO (2011) Management strategies for fibromyalgia. Open Access Rheumatol Res Rev 3:47-51
19. McIntyre RS, Soczynska JK, Woldeyoannes HO et al (2007) A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 8:1211-1219
20. McIntyre A, Paisley D, Kuoassi E, Gendron A (2013) Quetiapine fumarate extended release or the treatment of major depression with comorbid fibromyalgia syndrome a double-blind, randomized, placebo controlled study. Arthritis Rheum. doi: 10.1002/art38228
21. Moore N, McMillan P, Birur B, et al. (2011) Fibromyalgia: efficacy of quetiapine compared with placebo [Abstract no. NR08-48:333]. In 164th annual meeting of the American Psychiatric Association. Honolulu, Hawaii
22. Potvin S, Morin M, Cloutier C et al (2012) Add-on treatment of quetiapine for fibromyalgia. A pilot, randomized, double-blind, placebo-controlled 12-week trial. J Clin Psychopharmacol 2:684-687
23. Royuela A, Macías JA (1997) Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 9:81-94
24. Shemo M, Shemo JPD, Anderson M (2003) Beneficial effects of quetiapine treatment in patients with fibromyalgia [Abstract]. J Neuropsychiatry Clin Neurosci 15:282
25. Spielberger CD, Gorsuch RL, Lushene RE (2002) STAI Cuestionario de Ansiedad Estado-Rasgo. Manual (6 edición). Publicaciones de Psicología Aplicada. Serie menor número 124. TEA Ediciones S.A, Madrid
26. Vazquez C, Sanz J (1997) Fiabilidad y valores normales de la versión española del inventario para la depresión de Beck de 1978. Clin Salud 8:403-422
27. Wang Z, Kemp DE, Chan PK et al (2011) Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder. Int J Neuropsychopharmacol 14:131-142
28. Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 33:160-172
29. Wu CH, Farley JF, Gaynes BN (2012) The association between antidepressant dosage titration and medication adherence among patients with depression. Depress Anxiety 29:506-514